7月2日 - ** 以罕见病为重点的生物制药公司 Zevra Therapeutics 的 ZVRA.O 股价盘前上涨 ~2.57%，报 9.18 美元
** H.C. Wainwright给予ZVRA "买入 "评级，称其股价仍被低估
** 券商称，作为一家拥有商业和开发专长的领先罕见病公司，该公司目前的定位是回报投资者
** 将目标价定为 26 美元，较上一交易日收盘价上涨约 190.5
** 八家券商均将该股评为 "买入 "或更高评级；他们的预测中值为 25 美元 - LSEG
** 截至上次收盘，该股今年累计上涨约 7.3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.